EP1897590A1 - Method for carrying out a magnetic therapy of malignant neoplasms - Google Patents
Method for carrying out a magnetic therapy of malignant neoplasms Download PDFInfo
- Publication number
- EP1897590A1 EP1897590A1 EP05822675A EP05822675A EP1897590A1 EP 1897590 A1 EP1897590 A1 EP 1897590A1 EP 05822675 A EP05822675 A EP 05822675A EP 05822675 A EP05822675 A EP 05822675A EP 1897590 A1 EP1897590 A1 EP 1897590A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- tumor
- magnetic
- particles
- temperature
- metals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 75
- 238000000034 method Methods 0.000 title claims abstract description 57
- 201000011510 cancer Diseases 0.000 title claims abstract description 18
- 238000002653 magnetic therapy Methods 0.000 title claims description 4
- 239000002245 particle Substances 0.000 claims abstract description 34
- 239000000696 magnetic material Substances 0.000 claims abstract description 23
- 230000000694 effects Effects 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 13
- 229910045601 alloy Inorganic materials 0.000 claims abstract description 11
- 239000000956 alloy Substances 0.000 claims abstract description 11
- 229910052761 rare earth metal Inorganic materials 0.000 claims abstract description 7
- 230000036760 body temperature Effects 0.000 claims abstract description 5
- 229910000765 intermetallic Inorganic materials 0.000 claims abstract description 4
- 230000005291 magnetic effect Effects 0.000 claims description 40
- 238000010438 heat treatment Methods 0.000 claims description 20
- 230000007704 transition Effects 0.000 claims description 10
- 230000005672 electromagnetic field Effects 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 150000002910 rare earth metals Chemical class 0.000 claims description 4
- 229910000510 noble metal Inorganic materials 0.000 claims description 3
- 239000010948 rhodium Substances 0.000 claims description 3
- 229910000629 Rh alloy Inorganic materials 0.000 claims description 2
- OMEXLMPRODBZCG-UHFFFAOYSA-N iron rhodium Chemical compound [Fe].[Rh] OMEXLMPRODBZCG-UHFFFAOYSA-N 0.000 claims description 2
- 229910052723 transition metal Inorganic materials 0.000 claims 1
- 150000003624 transition metals Chemical class 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 abstract description 11
- 239000002184 metal Substances 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 5
- 238000000940 electromagnetic therapy Methods 0.000 abstract description 5
- 150000002739 metals Chemical class 0.000 abstract description 5
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000005302 magnetic ordering Effects 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 239000010970 precious metal Substances 0.000 abstract 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 18
- 210000004881 tumor cell Anatomy 0.000 description 15
- 239000000126 substance Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 206010020843 Hyperthermia Diseases 0.000 description 7
- 230000036031 hyperthermia Effects 0.000 description 7
- 206010028851 Necrosis Diseases 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 229940034982 antineoplastic agent Drugs 0.000 description 6
- 230000010102 embolization Effects 0.000 description 6
- 230000002977 hyperthermial effect Effects 0.000 description 6
- 229910052742 iron Inorganic materials 0.000 description 6
- 229910052710 silicon Inorganic materials 0.000 description 6
- 239000010703 silicon Substances 0.000 description 6
- 230000005294 ferromagnetic effect Effects 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000005670 electromagnetic radiation Effects 0.000 description 4
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 208000021328 arterial occlusion Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000002254 renal artery Anatomy 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010069729 Collateral circulation Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001994 activation Methods 0.000 description 2
- 230000008321 arterial blood flow Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000005347 demagnetization Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003302 ferromagnetic material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 230000005415 magnetization Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 229910000640 Fe alloy Inorganic materials 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 229910001030 Iron–nickel alloy Inorganic materials 0.000 description 1
- 208000008636 Neoplastic Processes Diseases 0.000 description 1
- 229910000990 Ni alloy Inorganic materials 0.000 description 1
- QKBGEGKCGLXDSG-UHFFFAOYSA-N [5-[[4,6-bis(aziridin-1-yl)-1,3,5-triazin-2-yl]amino]-2,2-dimethyl-1,3-dioxan-5-yl]methanol Chemical compound C1OC(C)(C)OCC1(CO)NC1=NC(N2CC2)=NC(N2CC2)=N1 QKBGEGKCGLXDSG-UHFFFAOYSA-N 0.000 description 1
- JJFQUNYBBJTESR-UHFFFAOYSA-N [P].[Mn].[Fe].[As] Chemical compound [P].[Mn].[Fe].[As] JJFQUNYBBJTESR-UHFFFAOYSA-N 0.000 description 1
- AABGKKDTOXGNDF-UHFFFAOYSA-N [Si].[Gd] Chemical compound [Si].[Gd] AABGKKDTOXGNDF-UHFFFAOYSA-N 0.000 description 1
- LVKVKSQVTJLPDE-UHFFFAOYSA-N [Si].[Ge].[Gd] Chemical compound [Si].[Ge].[Gd] LVKVKSQVTJLPDE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100001133 acute intoxication condition Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- NYOGMBUMDPBEJK-UHFFFAOYSA-N arsanylidynemanganese Chemical compound [As]#[Mn] NYOGMBUMDPBEJK-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000006467 collateral growth Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 230000005686 electrostatic field Effects 0.000 description 1
- 238000013161 embolization procedure Methods 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- KCBURWHJMQRZJG-UHFFFAOYSA-N gadolinium palladium Chemical compound [Pd].[Gd] KCBURWHJMQRZJG-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000010106 peripheral embolization Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000003144 traumatizing effect Effects 0.000 description 1
- 239000011882 ultra-fine particle Substances 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
- A61N1/403—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia
- A61N1/406—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia using implantable thermoseeds or injected particles for localized hyperthermia
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22C—ALLOYS
- C22C1/00—Making non-ferrous alloys
- C22C1/04—Making non-ferrous alloys by powder metallurgy
- C22C1/047—Making non-ferrous alloys by powder metallurgy comprising intermetallic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22C—ALLOYS
- C22C2202/00—Physical properties
- C22C2202/02—Magnetic
Definitions
- the present invention relates to physical methods of medical treatment and can be used in magnetotherapy of malignant neoplasm.
- Surgical treatment is the most effective in case of early detection of the tumor. With common types of tumors the surgical treatment is often can't be used or is not applicable.
- the most preferred method for conservative malignant tumor treatment is the selective chemotherapy which consists in the injection of antineoplastic agent into blood vessels that supply the tumor.
- malignant tumors have been more frequently treated by intraorganic arterial occlusion which is carried out in combination with chemotherapy or without it.
- Methods for tumor treatment by the intraorganic arterial occlusion which consists in the injection of the powder iron (reduced, reprecipitated or carbonyl iron) in the form of suspension followed by the location of said suspension in the specific area by means of the external magnetic field, said powder iron is suspended into the physiological solution, polyvinylpyrrolidone solution, albumine solution or other liquid medium.
- Such methods allow to occluse great and small vessels thus providing the ischemic necrosis of the tumor affected organ.
- the sure occlusion of the whole organ's vascular system can't be provided using the external magnetic field.
- the supply of the tumor can be maintained by means of the collateral circulation growth. Due to this such methods are not sufficiently effective, and first of all they are not effective for treatment locally spread tumors.
- Methods which comprises treating the tumor by the embolization of vessels with silicon compositions, where said silicon compositions solidify into the vascular bed.
- silicon compositions solidify into the vascular bed.
- the need for using external magnetic field is eliminated.
- there is a risk of thrombembolia because the embolizate can enter into the general system bloodstream.
- a method of selective infarct of a tumor is known according to which a silicon composition comprising carbonyl iron microspheres is injected into the tumor. Due to this the embolization procedure can be carried out into the magnetic field. This allows the newly formed embolus, before they are completely formed, to withstand the arterial blood flow, thus reducing the risk of the entering of said embolus into the general bloodstream and then into the vitally important systems and organs. Moreover, the addition of iron into the composition initiates the local granulomatosis, which results in the better defined fibrotization.
- Such method which is used for kidney tumor treatment, allows to occluse the bleeding vessels of antihomatosis pathologies (with providing low risk of peripheral embolization), and also allows to completely occluse the main renal artery as well as renal ramuses.
- Antiograms show that after a certain time kidneys, that have been occlused, contract and their parenchyma atrophies.
- This method is more effective and more reliable than those discussed above. However with a large size of the tumor mass this method can't provide the complete necrocitosis of the tumor cells. Moreover after a certain time the tumor supply can be re-established due to the collateral circulation growth.
- Treatment methods involve subjecting the tumors to ferromagnetic embolization followed by electromagnetic hyperthermia.
- the ischemic necrosis of the tumor affected organ which is provided by the embolization of said organ's vascular bed, is enhanced by the coagulation necrosis, which is provided by the heating.
- the more long-lasting remission can be expected, especially at the early stages of the neoplastic process.
- a method for treating kidney malignant tumors is known, according to which the arterial bed of a tumor affected kidney is subjected to chemical embolization by the oily solution of the 100mg of the dioxadet, and then, the main bed of the renal artery is blocked with the metal spiral.
- chemical embolization provides the greater survival percentage than the ordinary embolization.
- the tumor degradation results in the progressive intoxication which leads to the patient deterioration.
- Cellular elements of the tumor enter into the venous bloodstream together with the tumor degradation products. That's why the tumor dissimination followed by the metastasis still can be expected.
- US 5,236,410, 1993 discloses another method of tumor treatment.
- the method consists in selective catheterization of a hepatic artery or renal artery (in case of kidney tumor).
- a barium or strontium hexaferrite suspension in dioxadete oily solution is injected through a catheter under the X-ray control with simultaneous induction of the external magnetic field in the tumor area.
- the arterial bloodflow is then reduced by the metal spiral.
- the tumor is subjected to the ultrahigh frequency electromagnetic field or to the ultrasound until said tumor is heated up to the 43 - 43,5°C. After the required temperature has been reached the electromagnetic field or ultrasound exposure is kept during 5 - 45 minutes.
- the tumor is subjected to the puncture biopsy. If viable tumor cells are detected then the hyperthermia procedure is repeated.
- this method allows to reduce the risk of tumor cells and tumor degradation products entering into the general bloodstream. As result, the organism intoxication and risk of metastasis are also reduced. Embolisate's radiopacity allows monitoring the state of the tumor. The treatment can be repeated if required.
- This method is the most effective for tumor cells destruction in comparison with methods discussed above. It is used for the treatment of primary or metastatic liver and kidney tumors.
- the magnetic field strength should be very high to keep the magnetically controlled particles in the arterial bed of the affected organ.
- the high strength of the magnetic field results in the distortion of X-ray image during the angiographic study.
- the second disadvantage is that the possibility of fat thrombembolia is not eliminated even in case of removing the magnetic field. It relates mainly to cases when the patient conditions don't require arterial bloodstream reduction, and also when there are intraorganic and especially intratumoral venous-arterial shunts.
- dioxadete washing away This results in the reduction of dioxadete concentration into the tumor area and thus leads to the reduction of chemotherapeutical treatment effectiveness.
- RU 2065734, 27.08.1996 discloses a method comprising the treatment of tumor by injection of oily solution of a liposoluble antineoplastic agent, by the intraorganic arterial occlusion followed by the local electromagnetic hyperthermia of the tumor.
- the antineoplastic agent is injected before the occlusion.
- the occlusion is carried out using the ferrite-and-silicon composition.
- the hyperthermia is carried out in 3 - 4 weeks after the occlusion by the high frequency currents at 44 - 46°C during 45 - 60 minutes.
- the dioxadete in amount of 20 - 100mg which is added to the 5 - 10ml of maiodide or iodinelipol is preferred for use as the antineoplastic agent.
- the preferred ferritic-and-silicon composition is the carbonyl iron in amount of 2 - 4g, which is suspensed into the 20ml of dimethil-methil-vinyl-polysiloxane and oligo-dimethil-siloxane mixture, whereas the suspension is produced in the presence of chloroplatinic acid and oligo-hydride-siloxane in amount which is enough for the catalytic effect.
- the composition should be injected in amount which is sufficient for filling the arterial bed of the tumor.
- RU 2002133709, 20.06.2004 discloses a method for tumor treatment which includes the use of a therapeutic agent and radiation exposure.
- the therapeutic agent is prepared by the water electrolysis at 50 - 60°C during 40 - 45 minutes with the DC 0,45 - 0,5mA and 6 - 7V.
- the water which is full of electrons, ions and hydrated ions of the trace elements is subjected to the constant magnetic field (5000 - 1000 oersted) until its pH reaches 8,4 - 9,4, whereby the percentage ratio of components' masses in electrodes is following Ag 97,5- 99,5 Cu 1,5 - 0,28 Zn 0,85 - 0,21 Fe 0,15 - 0,1
- the above therapeutic agent is ingested in amount of 100 - 150g in the evening, at night and in the morning with the simultaneous radiation exposure of each tumor integumen by the negative charge electrostatic field (0,5-1 cm3/ oersted) during 10 - 15 minutes from the height of about 5 - 10mm. Then the tumor mass is subjected to the negative charges exposure.
- the negative charges field exposure on the skin integument of the tumor mass is carried out 3-4 times a day for 10-15 minutes.
- This problem is still urgent and needs more effective cancer cures.
- the information is given below which regards to the improved and innovative methods for oncolysis by the magnetic field.
- a method of hyperthermic electromagnetic therapy of malignant neoplasms is known, wherein the tumor is subjected to the local heating up to 42-44°C by HF, UHF or SHF electromagnetic radiation and then is kept at this temperature for 30 - 120 minutes (the temperature deviation should be ⁇ 0,5°C).
- the temperature of the area being heated is controlled by invasive needle thermocouple sensors having the diameter up to 1 mm, or by invasive catheter thermocouple sensors having the diameter up to 2 mm.
- the sensors are inserted into the area to be heated (Konoplyanikov A.T. Electromagnitnaya hypertermiya (microwave ultra high frequency) pri lecheni opukholevykh i neopukholevykh zabolevaniy. Physical medicine, 1991, pp. 1-11).
- a method of oncolysis using magnetic material wherein the said magnetic material consists of a magnetic medium and large-size ferromagnetic particles (5-20 micrometers and more). Said particles are inserted (implanted) into the tumor and then are subjected to the HF field exposure. This provides the heating to sufficient temperature at which the tumor degradates while healthy tissue remains vital, since the necrocytosis of healthy cells does not occur until 43,5°C ( US 4,323,056, 1980 ).
- the major drawbacks of this method are:
- a method of oncolysis using ferromagnetic material is known.
- Said ferromagnetic material consists of ultrafine metallic iron particles having the size of 0,2-1,0 micrometers.
- the method comprises injecting into a tumor a suspension of said ultrafine particles in an antineoplastic agent (8% gelatinome solution), wherein the tumor is then subjected to the HF field exposure ( RU 2026083 09/01/1995).
- This method allows to occluse large and small blood vessels thus providing the ischemic necrosis of a tumor affected organ.
- this method is not effective enough because it does not provide the total necrosis of tumor cells.
- a method for the hyperthermic electromagnetic therapy of malignant neoplasm is known according to which a suspension of fine magnetite particles (which have the size of 20-25 nm) is injected intravenously or intramuscularly into the tumor area. Then the tumor is heated. It shall be noted that the concentration of iron particles after they are injected into the area to be heated is more than 10 6 particles/cm 3 [3] ( Matushkin I.F., Tsybukov O.N., et al Ferromagnitnaya UF-hypertermiya subkletochnykh Appel zlokachestvennoy opukholi v experimente, Proceedings of the 2nd All-Russia symposium with international participants. Minsk 1990, , pp.47-48 ).
- heating is achieved by using electromagnetic waves of HF band (13,56MHz). Electromagnetic energy is supplied to the area to be heated through whip antennas which are invasively inserted into the said area. High contrast of the area to be heated in terms of the electromagnetic energy absorption coefficient increases the selectivity and efficiency of treatment. As a result, the tumor cells are heated more intensively in comparison with non-malignant cells.
- HF band 13,56MHz
- a method of carrying out magnetic therapy (hyperthermic electromagnetic therapy) of malignant neoplasms is known, whose technical essence and results provided are the closest to those of the inventive method.
- ferromagnetic magnetoresitive material
- Curie temperature Curie temperature
- the following substances can be used as the said ferromagnetic (magnetic material):
- the object of the present invention is to provide the increase of heat production by using more effective magnetic material and also by using a method which is fundamentally different from those described above and which is based on the so-called magnetocaloric effect (MCE).
- MCE magnetocaloric effect
- the above object is achieved by a method for carrying out the magnetic therapy of malignant neoplasms, according to which magnetic particles are injected into a tumor and then are heated by means of a heat which is produced due to MCE, whereas said particles have preferable size of for example 8 micrometer - 1 nanometer and consist of a material, characterized by having high magnetocaloric effect and magnetic phase transition temperature close to the human body temperature.
- Said material is selected from the group consisting of noble metals, rare-earth metals (elements), their alloys and intermetallic compounds.
- Magnetocaloric effect is defined as the heat release or heat absorption in a magnetic substance under exposure to magnetic field. If these processes occur under adiabatic conditions, the temperature of a substance specimen increases or decreases. The MCE was discovered by E. Warburg in 1881.
- MCE is based on the ability of any magnetic material to change its temperature and entropy under the magnetic field exposure just as in case of gas or vapour compression (for example in conventional refrigerators).
- the magnetic material temperature changes are caused by redistribution of intrinsic energy of the magnetic substance between the magnetic moment system of its atoms and crystal lattice.
- the magnetocaloric effect can be used particularly in the magnetic refrigeration technology, for example in systems for conditioning large spaces, in the equipment for food storages and more particularly in the development of industrial and household refrigerating systems.
- various magnetic materials can be used as a working medium.
- Thermomagnetic properties of magnets are determined by the magnetocaloric effect. The higher the rate of magnetocaloric effect, the more effective heat release or absorption in a magnetic substance under magnetic field exposure is. This provides the enhancement of magnetic materials properties and the enhancement of magnetotherapy efficiency for the treatment of different diseases (in this particular case the enhancement of the efficiency of malignant neoplasms magnetotherapy is achieved).
- Examples of materials which are used in the claimed method include materials with a high magnetocaloric effect and magnetic phase transition temperature close to the human body temperature (from 36°C up to approximately 37°C) are described in detail ( A.M. Tishin, Y.I. Spichkin Magnetocaloric effect and its application, Institute of Physics Publishing, Bristol and Philadelphia, 2003, p. 410-411 ). In particular said materials are
- the above magnetic material is used in the form of particles which have the size of for example 1,0 nanometer to 8 micrometer.
- Magnetic measurements show that the magnetic phase transition temperature of rare-earth metal (REM) alloys and compounds depends to a great extend on the concentration of metals and elements being melted together.
- the variation of a certain element content into the alloy allows to achieve the required magnetocaloric effect and to provide the required magnetic phase transition temperature which is close to the human body temperature.
- the magnetic phase transition occurs into a wide range of magnetic fields whose strength varies from units of kilooersted to 60 kilooersted and more.
- Magnetic material particles are produced in accordance with various known technologies, for example by plasma method at a temperature of 10000°C in inert atmosphere (such as argon atmosphere) using particles of a certain metal (element) or metals with initial particle size for example of 50-100 micrometers, or a method described in SU 1746162 , 07.07.1992.
- inert atmosphere such as argon atmosphere
- magnetic material particles are injected into a tumor in the form of a suspension or slurry in a pharmaceutically suitable medium such as water, physiological solution, polyvinylpyrrolidone, biopolymers, albumine, protein-A. Magnetic material particles can also be injected together with antineoplastic agent.
- a pharmaceutically suitable medium such as water, physiological solution, polyvinylpyrrolidone, biopolymers, albumine, protein-A.
- Magnetic material particles can also be injected together with antineoplastic agent.
- the above disclosed method can be implemented for example in the following way.
- the magnetic material Gd 7 Pd 3 in the form of 8 or 3 micrometer particles is injected into the tumor tissue and then is subjected to magnetic field exposure, whereas the strength of the said field is 50 kilooersted.
- the magnetic field can also be produced by a superconducting solenoid.
- the particles are pre-concentrated in a certain area of a tumor by subjecting to magnetic field gradient.
- Pre-concentrated in the tumor tissue particles of a magnetic material are uniformly heated by exposure to magnetic field. Due to the heat released as result of MCE, the tissues surrounding the particles are heated up to 40-42°C (313-315K), thus causing the tumor cells necrocytosis. Then, the field is deactivated and magnetic material particles are demagnetized (cooled). After the temperature decrease the particles are heated due to the thermal interchange with the human body and then are magnetized again. Thus, said particles are heated again to the required temperature under exposure to magnetic field and, in turn, heat the tumor affected tissues.
- the realization of a method according to the invention is based on the use of AMRC (active magnetic regenerative cycle), whereas magnetic particles of said materials act not only as a working medium, which provides heating and cooling under magnetization/demagnetization, but also as a heat generator.
- AMRC active magnetic regenerative cycle
- the above disclosed method of magnetotherapy (hyperthermia) according to the present invention promotes (possibly, in combination with pharmaceutical compositions) destruction of tumor cells without damaging healthy cells.
- the method according to the invention provides the increased effectiveness of malignant neoplasm theatment.
- the said method denotes a further improvement in solving this problem.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Materials Engineering (AREA)
- Biomedical Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mechanical Engineering (AREA)
- Metallurgy (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
- The present invention relates to physical methods of medical treatment and can be used in magnetotherapy of malignant neoplasm.
- The current methods for malignant tumors treatment are surgical, chemotherapeutic and radiation. Surgical treatment is the most effective in case of early detection of the tumor. With common types of tumors the surgical treatment is often can't be used or is not applicable.
- The most preferred method for conservative malignant tumor treatment is the selective chemotherapy which consists in the injection of antineoplastic agent into blood vessels that supply the tumor. In recent years, malignant tumors have been more frequently treated by intraorganic arterial occlusion which is carried out in combination with chemotherapy or without it.
- Recently magnetic field and magnetic materials have been known to gain wide usage in the production of dosage band and pharmaceutical products and also in magnetotherapy for diagnostics and treatment of various diseases.
- Methods are known for tumor treatment by the intraorganic arterial occlusion which consists in the injection of the powder iron (reduced, reprecipitated or carbonyl iron) in the form of suspension followed by the location of said suspension in the specific area by means of the external magnetic field, said powder iron is suspended into the physiological solution, polyvinylpyrrolidone solution, albumine solution or other liquid medium.
- Such methods allow to occluse great and small vessels thus providing the ischemic necrosis of the tumor affected organ. However sometimes the sure occlusion of the whole organ's vascular system can't be provided using the external magnetic field. The supply of the tumor can be maintained by means of the collateral circulation growth. Due to this such methods are not sufficiently effective, and first of all they are not effective for treatment locally spread tumors.
- Methods are known which comprises treating the tumor by the embolization of vessels with silicon compositions, where said silicon compositions solidify into the vascular bed. In this case the need for using external magnetic field is eliminated. However in this case there is a risk of thrombembolia because the embolizate can enter into the general system bloodstream.
- A method of selective infarct of a tumor is known according to which a silicon composition comprising carbonyl iron microspheres is injected into the tumor. Due to this the embolization procedure can be carried out into the magnetic field. This allows the newly formed embolus, before they are completely formed, to withstand the arterial blood flow, thus reducing the risk of the entering of said embolus into the general bloodstream and then into the vitally important systems and organs. Moreover, the addition of iron into the composition initiates the local granulomatosis, which results in the better defined fibrotization. Such method, which is used for kidney tumor treatment, allows to occluse the bleeding vessels of antihomatosis pathologies (with providing low risk of peripheral embolization), and also allows to completely occluse the main renal artery as well as renal ramuses. Antiograms show that after a certain time kidneys, that have been occlused, contract and their parenchyma atrophies.
- This method is more effective and more reliable than those discussed above. However with a large size of the tumor mass this method can't provide the complete necrocitosis of the tumor cells. Moreover after a certain time the tumor supply can be re-established due to the collateral circulation growth.
- Treatment methods are known which involve subjecting the tumors to ferromagnetic embolization followed by electromagnetic hyperthermia. In this case the ischemic necrosis of the tumor affected organ, which is provided by the embolization of said organ's vascular bed, is enhanced by the coagulation necrosis, which is provided by the heating. Obviously in this case the more long-lasting remission can be expected, especially at the early stages of the neoplastic process.
- A method for treating kidney malignant tumors is known, according to which the arterial bed of a tumor affected kidney is subjected to chemical embolization by the oily solution of the 100mg of the dioxadet, and then, the main bed of the renal artery is blocked with the metal spiral. According to this method, chemical embolization provides the greater survival percentage than the ordinary embolization. However the tumor degradation results in the progressive intoxication which leads to the patient deterioration. Cellular elements of the tumor enter into the venous bloodstream together with the tumor degradation products. That's why the tumor dissimination followed by the metastasis still can be expected.
-
US 5,236,410, 1993 , discloses another method of tumor treatment. The method consists in selective catheterization of a hepatic artery or renal artery (in case of kidney tumor). A barium or strontium hexaferrite suspension in dioxadete oily solution is injected through a catheter under the X-ray control with simultaneous induction of the external magnetic field in the tumor area. In case of the large size of a tumor mass the arterial bloodflow is then reduced by the metal spiral. After 1 - 3 days the tumor is subjected to the ultrahigh frequency electromagnetic field or to the ultrasound until said tumor is heated up to the 43 - 43,5°C. After the required temperature has been reached the electromagnetic field or ultrasound exposure is kept during 5 - 45 minutes. On the 6 - 7th and 15 - 20th days and also after 3 - 6 months the tumor is subjected to the puncture biopsy. If viable tumor cells are detected then the hyperthermia procedure is repeated. - Because the tumor cells are simultaneously subjected to chemical treatment and hyperthermia action, this method allows to reduce the risk of tumor cells and tumor degradation products entering into the general bloodstream. As result, the organism intoxication and risk of metastasis are also reduced. Embolisate's radiopacity allows monitoring the state of the tumor. The treatment can be repeated if required.
- This method is the most effective for tumor cells destruction in comparison with methods discussed above. It is used for the treatment of primary or metastatic liver and kidney tumors.
- However this method has some disadvantages. First of all, the magnetic field strength should be very high to keep the magnetically controlled particles in the arterial bed of the affected organ. The high strength of the magnetic field results in the distortion of X-ray image during the angiographic study. The second disadvantage is that the possibility of fat thrombembolia is not eliminated even in case of removing the magnetic field. It relates mainly to cases when the patient conditions don't require arterial bloodstream reduction, and also when there are intraorganic and especially intratumoral venous-arterial shunts. In addition, there is a risk of dioxadete washing away. This results in the reduction of dioxadete concentration into the tumor area and thus leads to the reduction of chemotherapeutical treatment effectiveness. This risk is reduced to a great extend in case of arterial bloodstream reduction which is made when the tumor mass is large sized. If the metal spiral is used for this purpose then during the hyperthermia there is a risk of the strong heating of said metal spiral and of surrounding healthy tissues. On the other hand, the insufficient heating can't provide the complete necrosis of the tumor. The depth of the ultrahigh frequency currents penetration does not exceed 7 centimeters. That's why the presence of viable tumor cells into the large sized tumor mass is associated with the risk of collateral growth in the future. In this case the heating can contribute to the bloodstream establishing and tumor growth.
-
RU 2065734, 27.08.1996 - The dioxadete in amount of 20 - 100mg which is added to the 5 - 10ml of maiodide or iodinelipol is preferred for use as the antineoplastic agent. The preferred ferritic-and-silicon composition is the carbonyl iron in amount of 2 - 4g, which is suspensed into the 20ml of dimethil-methil-vinyl-polysiloxane and oligo-dimethil-siloxane mixture, whereas the suspension is produced in the presence of chloroplatinic acid and oligo-hydride-siloxane in amount which is enough for the catalytic effect. The composition should be injected in amount which is sufficient for filling the arterial bed of the tumor.
- If there is a residual bloodstream after the ferrite-and-silicon occlusion has been completed it is advisable to...
-
RU 2002133709, 20.06.2004
Ag 97,5- 99,5
Cu 1,5 - 0,28
Zn 0,85 - 0,21
Fe 0,15 - 0,1 - The above therapeutic agent is ingested in amount of 100 - 150g in the evening, at night and in the morning with the simultaneous radiation exposure of each tumor integumen by the negative charge electrostatic field (0,5-1 cm3/ oersted) during 10 - 15 minutes from the height of about 5 - 10mm. Then the tumor mass is subjected to the negative charges exposure.
- The negative charges field exposure on the skin integument of the tumor mass is carried out 3-4 times a day for 10-15 minutes. Though the wide variety of methods for malignant tumor treatment are known, however this problem is still urgent and needs more effective cancer cures. The information is given below which regards to the improved and innovative methods for oncolysis by the magnetic field.
- It is known that temperatures under 39°C stimulate tumor growth, at temperatures higher than 39°C the viability of tumor cells is weakened, and temperatures of 40-42°C cause necrocytosis of tumor cells. Once subjected to 42°C for one hour, the tumor tissue undergoes irreversible changes. Non-malignant tissue is still vital after subjection to 43°C for 150 minutes. Even at 46°C non-malignant tissue remains vital for up to one hour. Thus, the damage rate of the tumor depends on the temperature level and exposure time (Kulemin V.V., Kotomin S.V., Albitsky V.B, Varigin Y.A. «Obschaya upravlyaemaya eksogennaya gipertermiya s hypertermiey i chimioterapiey pod narcosom s hypotermiey mozga pri lechenii zlokachestvennykh opukholey. Physiceskaya medicina, 1991, pp. 21- 29»).
- A method of hyperthermic electromagnetic therapy of malignant neoplasms is known, wherein the tumor is subjected to the local heating up to 42-44°C by HF, UHF or SHF electromagnetic radiation and then is kept at this temperature for 30 - 120 minutes (the temperature deviation should be ±0,5°C). The temperature of the area being heated is controlled by invasive needle thermocouple sensors having the diameter up to 1 mm, or by invasive catheter thermocouple sensors having the diameter up to 2 mm. The sensors are inserted into the area to be heated (Konoplyanikov A.T. Electromagnitnaya hypertermiya (microwave ultra high frequency) pri lecheni opukholevykh i neopukholevykh zabolevaniy. Physical medicine, 1991, pp. 1-11).
- A method of oncolysis using magnetic material is known, wherein the said magnetic material consists of a magnetic medium and large-size ferromagnetic particles (5-20 micrometers and more). Said particles are inserted (implanted) into the tumor and then are subjected to the HF field exposure. This provides the heating to sufficient temperature at which the tumor degradates while healthy tissue remains vital, since the necrocytosis of healthy cells does not occur until 43,5°C (
US 4,323,056, 1980 ). The major drawbacks of this method are: - 1. Relatively large particles cannot be injected into the dense structure tumor, while the use of small particles is not effective since they are poorly heated in the HF field;
- 2. The heating of tumor tissue is not uniform, that creates the risk of tumor growth initiation, since at 38-41°C the initiation of tumor cells proliferation occurs.
- 3. When the temperature reaches the level, which is lethal for tumor cells, the necrocytosis of said tumor cells occurs. This results in the emission of tumor degradation products into the blood-vascular system. In this case, acute intoxication of the organism occurs which sometimes can be fatal.
- A method of oncolysis using ferromagnetic material is known. Said ferromagnetic material consists of ultrafine metallic iron particles having the size of 0,2-1,0 micrometers. The method comprises injecting into a tumor a suspension of said ultrafine particles in an antineoplastic agent (8% gelatinome solution), wherein the tumor is then subjected to the HF field exposure (
RU 2026083 - This method allows to occluse large and small blood vessels thus providing the ischemic necrosis of a tumor affected organ. However, this method is not effective enough because it does not provide the total necrosis of tumor cells.
- A method for the hyperthermic electromagnetic therapy of malignant neoplasm is known according to which a suspension of fine magnetite particles (which have the size of 20-25 nm) is injected intravenously or intramuscularly into the tumor area. Then the tumor is heated. It shall be noted that the concentration of iron particles after they are injected into the area to be heated is more than 106 particles/cm3 [3] (Matushkin I.F., Tsybukov O.N., et al Ferromagnitnaya UF-hypertermiya subkletochnykh struktur zlokachestvennoy opukholi v experimente, Proceedings of the 2nd All-Russia symposium with international participants. Minsk 1990, , pp.47-48).
- In the known method, heating is achieved by using electromagnetic waves of HF band (13,56MHz). Electromagnetic energy is supplied to the area to be heated through whip antennas which are invasively inserted into the said area. High contrast of the area to be heated in terms of the electromagnetic energy absorption coefficient increases the selectivity and efficiency of treatment. As a result, the tumor cells are heated more intensively in comparison with non-malignant cells. However, the above mentioned known methods for hyperthermic elecrtomagnetic therapy have some drawbacks:
- invasive insertion of extraneous bodies, such as whip antennas and temperature sensors, is highly traumatizing to the area or organ to be heated;
- no reliable information about the temperature distribution in the area being heated is available because sensors measure the temperature in their close proximity areas only;
- heating of tissues is not uniform because there are no physical mechanisms which can provide the self-holding temperature equalization through the whole area being heated; the thermal conductivity of tissues could act as said mechanism, but it is obvious that the thermal conductivity can't provide uniform distribution of the temperature and uniform exposure time for all parts of the area being heated, because a sensor which reaches the predetermined temperature first will deactivate the whole heating system thus causing the cooling of area to be heated;
- frequent activation and deactivation of an electromagnetic radiation generator reduces its life, since its life time depends on the number of activations and deactivations rather than on the continuous work time.
- The use of HF and SHF electromagnetic radiation has the following disadvantages. There are two ways of heating substances using high frequency alternating magnetic field:
- heating of a conductor by ohmic losses of eddy currents being induced (in case being discussed the high frequency alternative currents are induced into small magnetite particles; said currents induce surface charges on the opposite sides of the particle);
- dielectric heating due to dielectric losses which occur in electromagnetic field absorption. If HF band electromagnetic field is used, heating by eddy currents is more effective. If SHF band electromagnetic field is used, dielectric heating is more effective due to the skin effect. Thus, in HF hyperthermic therapy, basically, magnetite particles are heated, while the tissue heating achieved via thermal conductivity. In addition, temperature sensors undergo the most strong heating, as they have much greater size than magnetite particles. Therefore, the temperature measurement reliability is intolerable.
- A method of carrying out magnetic therapy (hyperthermic electromagnetic therapy) of malignant neoplasms is known, whose technical essence and results provided are the closest to those of the inventive method. In the known method, ferromagnetic (magnetic material) is used, wherein the size of ferromagnetic particles is 2-30 micrometers and its Curie temperature (Curie point) is within the range of 42-45°C. The following substances can be used as the said ferromagnetic (magnetic material):
- iron and nickel alloy (Fe-Ni 30-40, whereas the Curie temperature is within the range of 35-45°C),
- nickel-and-copper based alloy,
- material which exhibits a metal-to-dielectric or metal-to-semiconductor or dielectric-to-metal phase transition, whereas the phase transition temperature is within the range of 42-45°C (such as VO 2-based alloy which includes some alloy additives required for the accurate adjustment of the phase transition temperature).
These materials are used for carrying out the hyperthermic electromagnetic therapy of malignant neoplasms. A suspension of said materials particles are injected into a tumor tissue and then are heated by electromagnetic field energy. HF or SHF radiation is used as the electromagnetic radiation. The wattage of SHF radiation generator is 5-100W (RU 2082458, 27.06.1997
The first and foremost disadvantage of this method is the harmful effect of HF and SHF radiation on a human organism. Though lately the frequency of radiation being used is reduced down to megahertz range and in this case the long-term irradiation doesn't hurt the organism, the method still did not find use for tumor treatment since it does not provide the required effect. The main reason for the method inefficiency is supposedly that hysteresis loop of Fe, Ni and Cu-based alloys is not sufficiently wide and its form does not allow to provide the required heat production during reverse magnetization. - In view of the above, the object of the present invention is to provide the increase of heat production by using more effective magnetic material and also by using a method which is fundamentally different from those described above and which is based on the so-called magnetocaloric effect (MCE).
- The above object is achieved by a method for carrying out the magnetic therapy of malignant neoplasms, according to which magnetic particles are injected into a tumor and then are heated by means of a heat which is produced due to MCE, whereas said particles have preferable size of for example 8 micrometer - 1 nanometer and consist of a material, characterized by having high magnetocaloric effect and magnetic phase transition temperature close to the human body temperature. Said material is selected from the group consisting of noble metals, rare-earth metals (elements), their alloys and intermetallic compounds.
- Magnetocaloric effect is defined as the heat release or heat absorption in a magnetic substance under exposure to magnetic field. If these processes occur under adiabatic conditions, the temperature of a substance specimen increases or decreases. The MCE was discovered by E. Warburg in 1881.
- MCE is based on the ability of any magnetic material to change its temperature and entropy under the magnetic field exposure just as in case of gas or vapour compression (for example in conventional refrigerators).
- The magnetic material temperature changes are caused by redistribution of intrinsic energy of the magnetic substance between the magnetic moment system of its atoms and crystal lattice.
- The magnetocaloric effect can be used particularly in the magnetic refrigeration technology, for example in systems for conditioning large spaces, in the equipment for food storages and more particularly in the development of industrial and household refrigerating systems. In such magnetic refrigerators, whose function is based on the magnetocaloric refrigeration principle, various magnetic materials can be used as a working medium.
- Thermomagnetic properties of magnets are determined by the magnetocaloric effect. The higher the rate of magnetocaloric effect, the more effective heat release or absorption in a magnetic substance under magnetic field exposure is. This provides the enhancement of magnetic materials properties and the enhancement of magnetotherapy efficiency for the treatment of different diseases (in this particular case the enhancement of the efficiency of malignant neoplasms magnetotherapy is achieved).
- Examples of materials which are used in the claimed method include materials with a high magnetocaloric effect and magnetic phase transition temperature close to the human body temperature (from 36°C up to approximately 37°C) are described in detail (A.M. Tishin, Y.I. Spichkin Magnetocaloric effect and its application, Institute of Physics Publishing, Bristol and Philadelphia, 2003, p. 410-411). In particular said materials are
- noble metals (rhodium, palladium, platinum) based alloys,
- rare-earth elements (metals) such as gadolinium Gd (whose Curie temperature is about 295K and whose MCE is ΔT=5,8K for H=2T),
- alloys or intermetallic compounds of rare-earth elements (metals), such as iron-rhodium alloy Fe 0,49 Rh 0,51 (whose antiferromagnetism-ferromagnetism magnetic phase transition temperature is about 310-316K and whose MCE reaches 13K in 2T range),
- gadolinium-silicon Gd 5 Si 4 (whose maximum MCE temperature is ΔT=8,8K for T=336K and H=5T),
- gadolinium-silicon-germanium Gd 5 Si 2,06 Ge 1,94 (ΔT=8K in 5T range and for T=306K),
- gadolinium-palladium Gd 7 Pd 3 (ΔT=8,5K for T=323K and =5T),
- manganese-iron-phosphorus-arsenic MnFeP 0,35 As 0,65 (whose maximum MCE point is T=332K),
- manganese-arsenic MnAs (ΔT=13K for T=318K and H=5T) and others.
- The above magnetic material is used in the form of particles which have the size of for example 1,0 nanometer to 8 micrometer. Magnetic measurements show that the magnetic phase transition temperature of rare-earth metal (REM) alloys and compounds depends to a great extend on the concentration of metals and elements being melted together. The variation of a certain element content into the alloy allows to achieve the required magnetocaloric effect and to provide the required magnetic phase transition temperature which is close to the human body temperature. As a rule the magnetic phase transition occurs into a wide range of magnetic fields whose strength varies from units of kilooersted to 60 kilooersted and more.
- Magnetic material particles are produced in accordance with various known technologies, for example by plasma method at a temperature of 10000°C in inert atmosphere (such as argon atmosphere) using particles of a certain metal (element) or metals with initial particle size for example of 50-100 micrometers, or a method described in
SU 1746162 - According to the method of the present invention, magnetic material particles are injected into a tumor in the form of a suspension or slurry in a pharmaceutically suitable medium such as water, physiological solution, polyvinylpyrrolidone, biopolymers, albumine, protein-A. Magnetic material particles can also be injected together with antineoplastic agent.
- The above disclosed method can be implemented for example in the following way. The magnetic material Gd 7 Pd 3 in the form of 8 or 3 micrometer particles is injected into the tumor tissue and then is subjected to magnetic field exposure, whereas the strength of the said field is 50 kilooersted. In the heating step, the magnetic material is magnetized in adiabatic conditions by quick setting of the constant magnetic field that results in the temperature increase by the magnitude which is equal to the magnetocaloric effect (ΔT=7K for T=310K). Then, the magnetic field is deactivated that causes adiabatic demagnetization.
- The following equipment was used in the present example embodiment:
- a constant magnet (magnetic field),
- a magnetic material in the form of particles,
- auxiliary devices suitable for injection of magnetic material into tumor tissue and further transportation of the magnetic material and its fixation as required.
- The magnetic field can also be produced by a superconducting solenoid. The particles are pre-concentrated in a certain area of a tumor by subjecting to magnetic field gradient.
- Pre-concentrated in the tumor tissue particles of a magnetic material are uniformly heated by exposure to magnetic field. Due to the heat released as result of MCE, the tissues surrounding the particles are heated up to 40-42°C (313-315K), thus causing the tumor cells necrocytosis. Then, the field is deactivated and magnetic material particles are demagnetized (cooled). After the temperature decrease the particles are heated due to the thermal interchange with the human body and then are magnetized again. Thus, said particles are heated again to the required temperature under exposure to magnetic field and, in turn, heat the tumor affected tissues. Thus, the realization of a method according to the invention is based on the use of AMRC (active magnetic regenerative cycle), whereas magnetic particles of said materials act not only as a working medium, which provides heating and cooling under magnetization/demagnetization, but also as a heat generator.
- The above disclosed method of magnetotherapy (hyperthermia)according to the present invention promotes (possibly, in combination with pharmaceutical compositions) destruction of tumor cells without damaging healthy cells.
- Thus, the method according to the invention provides the increased effectiveness of malignant neoplasm theatment. The said method denotes a further improvement in solving this problem.
Claims (2)
- A method of magnetic therapy of malignant neoplasms, comprising injection of particles into a tumor tissue followed by heating with electromagnetic field energy, characterized in that said particles consist of a material which has high magnetocaloric effect and magnetic phase transition temperature close to the human body temperature, wherein the said material is selected from the group consisting of rare-earth metals, transition metals, noble metals and their alloys and intermetallic compounds.
- A method according to claim 1, characterized in that particles of iron-rhodium alloy, in particular of Fe 0,49 Rh 0,51, are used as a magnetic material.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2005118803/14A RU2295933C2 (en) | 2005-06-17 | 2005-06-17 | Method for carrying out malignant neoplasm magnetic therapy |
PCT/RU2005/000462 WO2006135270A1 (en) | 2005-06-17 | 2005-09-12 | Method for carrying out a magnetic therapy of malignant neoplasms |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1897590A1 true EP1897590A1 (en) | 2008-03-12 |
EP1897590A4 EP1897590A4 (en) | 2009-04-22 |
EP1897590B1 EP1897590B1 (en) | 2016-11-09 |
Family
ID=37532545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05822675.4A Not-in-force EP1897590B1 (en) | 2005-06-17 | 2005-09-12 | Preparation for use in a method of magnetic therapy of malignant neoplasms |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1897590B1 (en) |
RU (1) | RU2295933C2 (en) |
WO (1) | WO2006135270A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011033084A1 (en) * | 2009-09-21 | 2011-03-24 | Basf Se | Substrates comprising switchable ferromagnetic nanoparticles |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2373957C2 (en) * | 2006-10-13 | 2009-11-27 | Александр Метталинович Тишин | Therapeutic and diagnostic drug and biologically active substance carrier and application thereof for making drugs and method of regulated controlled drug or biologically active substance delivery with regulated desorption |
JP5750098B2 (en) * | 2009-05-08 | 2015-07-15 | コーニンクレッカ フィリップス エヌ ヴェ | Apparatus and method for heating magnetic materials |
RU2497489C1 (en) * | 2012-06-04 | 2013-11-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кемеровский технологический институт пищевой промышленности" | Method for local induction heating of biological tissues |
RU2525121C1 (en) * | 2013-02-13 | 2014-08-10 | Закрытое акционерное общество "Волга-Авиасервис" | Magnetic therapy apparatus |
RU2582977C2 (en) * | 2014-08-11 | 2016-04-27 | Общество с ограниченной ответственностью "Фармаг" | Device for physiotherapeutic magnetic-heat effect in preventing, treating and pathology proctologic diseases |
RU2633918C9 (en) * | 2016-04-01 | 2017-12-28 | Общество с ограниченной ответственностью "Фармаг" | Method for treatment of malignant new-formations by magnetic hyperthermia and pharmaceutical compositions for application in indicated method |
WO2018100402A1 (en) * | 2016-12-02 | 2018-06-07 | Сургуладзе БЕСИКИ | Preparation for the treatment of malignant tumors |
EP3607335A4 (en) * | 2017-04-05 | 2021-01-13 | Howard Hughes Medical Institute | Magnetic apparatus |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030028071A1 (en) * | 2001-07-25 | 2003-02-06 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4323056A (en) | 1980-05-19 | 1982-04-06 | Corning Glass Works | Radio frequency induced hyperthermia for tumor therapy |
RU2026083C1 (en) | 1989-12-21 | 1995-01-09 | Российский государственный медицинский университет | Method of destroying tumoral cells |
SU1746162A1 (en) | 1990-03-30 | 1992-07-07 | МГУ им.М.В.Ломоносова | Working medium of magnetic refrigerating machine |
US5236410A (en) | 1990-08-02 | 1993-08-17 | Ferrotherm International, Inc. | Tumor treatment method |
RU2082458C1 (en) | 1993-11-22 | 1997-06-27 | Александр Евгеньевич Дубинов | Method to conduct hyperthermic electromagnetic therapy of malignant neoplasm |
RU2065734C1 (en) | 1995-05-16 | 1996-08-27 | Центральный научно-исследовательский рентгено-радиологический институт МЗ РФ | Method of treatment of parenchymatous organ tumors |
JP2005090921A (en) * | 2003-09-19 | 2005-04-07 | Canon Inc | Temperature controlling device using magnetic body |
-
2005
- 2005-06-17 RU RU2005118803/14A patent/RU2295933C2/en not_active IP Right Cessation
- 2005-09-12 WO PCT/RU2005/000462 patent/WO2006135270A1/en active Application Filing
- 2005-09-12 EP EP05822675.4A patent/EP1897590B1/en not_active Not-in-force
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030028071A1 (en) * | 2001-07-25 | 2003-02-06 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
Non-Patent Citations (1)
Title |
---|
See also references of WO2006135270A1 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011033084A1 (en) * | 2009-09-21 | 2011-03-24 | Basf Se | Substrates comprising switchable ferromagnetic nanoparticles |
CN102714080A (en) * | 2009-09-21 | 2012-10-03 | 巴斯夫欧洲公司 | Substrates comprising switchable ferromagnetic nanoparticles |
US8632814B2 (en) | 2009-09-21 | 2014-01-21 | Basf Se | Substrates comprising switchable ferromagnetic nanoparticles |
AU2010297237B2 (en) * | 2009-09-21 | 2015-08-20 | Technische Universiteit Delft | Substrates comprising switchable ferromagnetic nanoparticles |
TWI504397B (en) * | 2009-09-21 | 2015-10-21 | Basf Se | Substrates comprising switchable ferromagnetic nanoparticles |
Also Published As
Publication number | Publication date |
---|---|
RU2295933C2 (en) | 2007-03-27 |
WO2006135270A1 (en) | 2006-12-21 |
EP1897590A4 (en) | 2009-04-22 |
EP1897590B1 (en) | 2016-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1897590B1 (en) | Preparation for use in a method of magnetic therapy of malignant neoplasms | |
Hedayatnasab et al. | Review on magnetic nanoparticles for magnetic nanofluid hyperthermia application | |
Deatsch et al. | Heating efficiency in magnetic nanoparticle hyperthermia | |
Gil et al. | Nanopharmacy: Inorganic nanoscale devices as vectors and active compounds | |
Moroz et al. | Targeting liver tumors with hyperthermia: ferromagnetic embolization in a rabbit liver tumor model | |
Hilger et al. | Electromagnetic heating of breast tumors in interventional radiology: in vitro and in vivo studies in human cadavers and mice | |
Lin et al. | In vitro feasibility study of the use of a magnetic electrospun chitosan nanofiber composite for hyperthermia treatment of tumor cells | |
Kuznetsov et al. | Local radiofrequency-induced hyperthermia using CuNi nanoparticles with therapeutically suitable Curie temperature | |
Dahiya et al. | Metal–ferrite nanocomposites for targeted drug delivery | |
RU2373957C2 (en) | Therapeutic and diagnostic drug and biologically active substance carrier and application thereof for making drugs and method of regulated controlled drug or biologically active substance delivery with regulated desorption | |
Savliwala et al. | Magnetic nanoparticles | |
M Tishin et al. | Developing antitumor magnetic hyperthermia: principles, materials and devices | |
JPH11197257A (en) | Improvement of hysteresis thermotherapy defining target as tissue therapy | |
Tseng et al. | Localised heating of tumours utilising injectable magnetic nanoparticles for hyperthermia cancer therapy | |
JP2009051752A (en) | Magnetic particle-containing drug carrier and therapeutic device using the same | |
EP3363496A1 (en) | Magnetic field oscillating at several frequencies for improving efficacy and/or reducing toxicity of magnetic hyperthermia | |
EP1594571B1 (en) | Microparticles for selectively targeted hyperthermia | |
Engelmann | Assessing magnetic fluid hyperthermia: magnetic relaxation simulation, modeling of nanoparticle uptake inside pancreatic tumor cells and in vitro efficacy | |
ES2662962T3 (en) | Procedure for the production of submicron particles and their therapeutic use in oncology with a specific device | |
Watanabe et al. | Development of a second-generation radiofrequency ablation using sintered MgFe 2O 4 needles and alternating magnetic field for human cancer therapy | |
US7448389B1 (en) | Method and kit for inducing hypoxia in tumors through the use of a magnetic fluid | |
RU2633918C2 (en) | Method for treatment of malignant new-formations by magnetic hyperthermia and pharmaceutical compositions for application in indicated method | |
EP3359141B1 (en) | Mixture of lafesih magnetic nanoparticles with different curie temperatures to improve inductive heating efficiency for hyperthermia therapy | |
Angelakeris et al. | Can commercial ferrofluids be exploited in AC magnetic hyperthermia treatment to address diverse biomedical aspects? | |
Guardia et al. | Magnetic nanoparticles for magnetic hyperthermia and controlled drug delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080117 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: TISHIN, ALEKSANDR METTALINOVICH |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: TISHIN, ALEKSANDR METTALINOVICH |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20090323 |
|
17Q | First examination report despatched |
Effective date: 20100322 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: TISHIN, ALEKSANDR METTALINOVICH |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: TISHIN, ALEKSANDR METTALINOVICH |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20160509 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 843328 Country of ref document: AT Kind code of ref document: T Effective date: 20161115 Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602005050664 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161109 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20161109 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 843328 Country of ref document: AT Kind code of ref document: T Effective date: 20161109 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161109 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161109 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170210 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161109 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170309 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161109 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161109 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161109 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161109 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170309 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161109 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161109 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161109 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161109 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161109 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602005050664 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161109 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170209 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161109 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20170810 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161109 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602005050664 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20170912 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161109 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170912 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20180531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170912 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170930 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170912 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170930 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180404 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171002 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20050912 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161109 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161109 |